Afayxs, Agile Therapeutics Partner to Expand Twirla Access

Agile Therapeutics, Inc. recently announced a new alliance with Afaxys Pharma, LLC to promote levonorgestrel and ethinyl estradiol (Twirla) transdermal system.

Twirla is an effective, low-dose contraceptive option in a non-daily, non-invasive patch. It is a once-weekly patch that contains levonorgestrel and ethinyl estradiol.

The partnership will help Americans who rely on community and public health centers get access to Twirla. Afaxys is a leading provider of innovative contraceptive options, making this partnership strategic and beneficial for all in the US family planning community.

“Afaxys and Agile Therapeutics are aligned on a mutual goal to provide reliable, affordable contraceptive access to women on their sexual and reproductive health journeys,” said Ronda Dean, President, CEO & Co-Founder of Afaxys. “We are committed to community and public health patients and providers, and this alliance will empower women with one more reliable family planning option to consider as they work with their physicians to choose the method of contraception that is right for them.”1

“This strategic agreement with Afaxys, a recognized leader in the public health system, will help ensure that Twirla is available, accessible and affordable to a much broader group of patients who can benefit from it,” commented Al Altomari, Chairman and CEO of Agile Therapeutics. “We look forward to advancing women’s reproductive health together.”1

Twirla is an effective, low-dose contraceptive option in a non-daily, non-invasive patch. It is a once-weekly patch that contains levonorgestrel and ethinyl estradiol.

The partnership will help Americans who rely on community and public health centers get access to Twirla. Afaxys is a leading provider of innovative contraceptive options, making this partnership strategic and beneficial for all in the US family planning community.

“Afaxys and Agile Therapeutics are aligned on a mutual goal to provide reliable, affordable contraceptive access to women on their sexual and reproductive health journeys,” said Ronda Dean, President, CEO & Co-Founder of Afaxys. “We are committed to community and public health patients and providers, and this alliance will empower women with one more reliable family planning option to consider as they work with their physicians to choose the method of contraception that is right for them.”1

“This strategic agreement with Afaxys, a recognized leader in the public health system, will help ensure that Twirla is available, accessible and affordable to a much broader group of patients who can benefit from it,” commented Al Altomari, Chairman and CEO of Agile Therapeutics. “We look forward to advancing women’s reproductive health together.”1

This article originally appeared on Contemporary Ob/Gyn.

Reference

  1. Agile Therapeutics and Afaxys Partner to Expand Access to Twirla (Levonorgestrel and Ethinyl Estradiol) Transdermal System | Agile Therapeutics. Agile Therapeutics. Published 2022. Accessed January 23, 2022. https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-and-afaxys-partner-expand-access-twirlar
  2. Agile Therapeutics and Afaxys Partner to Expand Access to Twirla (Levonorgestrel and Ethinyl Estradiol) Transdermal System | Agile Therapeutics. Agile Therapeutics. Published 2022. Accessed January 23, 2022. https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-and-afaxys-partner-expand-access-twirlar